|1.||Toyoshima, Takeshi: 2 articles (08/2012 - 04/2008)|
|2.||Seeber, S: 2 articles (05/2002 - 06/2001)|
|3.||Kasimir-Bauer, S: 2 articles (05/2002 - 06/2001)|
|4.||Kapsner, Thomas: 2 articles (01/2002 - 01/2002)|
|5.||Wimberger, Pauline: 2 articles (01/2002 - 01/2002)|
|6.||Hepp, Hermann: 2 articles (01/2002 - 01/2002)|
|7.||Hillemanns, Peter: 2 articles (01/2002 - 01/2002)|
|8.||Kimmig, Rainer: 2 articles (01/2002 - 01/2002)|
|9.||Kawano, Shintaro: 1 article (08/2012)|
|10.||Oobu, Kazunari: 1 article (08/2012)|
|1.||Breast Neoplasms (Breast Cancer)
05/01/2002 - "We monitored CK+/17-1A+ cells in the BM and PBSC and studied Her-2/neu serum levels of patients with locally advanced (n=13, group 1) and metastatic breast cancer (n=30, group 2). "
05/01/2002 - "In a second study, we monitored cytokeratin (CK)/17-1A positive cells in the BM and peripheral blood stem cells (PBSC) to evaluate whether dose intensive or high-dose (HD)-chemotherapy can eliminate micrometastases in high-risk breast cancer patients. "
01/01/2008 - "Using breast cancer tumour microarrays, immunohistochemical expression of cytokeratin (CK)-5/6, CK-14 and CK-17 was evaluated in breast tumours from BRCA1 families (n = 46), BRCA2 families (n = 40), non-BRCA1/BRCA2 families (n = 358) and familial breast cancer patients with one first-degree relative affected by breast or ovarian cancer (n = 270), as well as from patients with sporadic breast cancer (n = 364). "
01/01/2002 - "Epithelial cells were labeled by FITC-conjugated cytokeratin antibody (CK 5, 6, 8, and CK 17) prior to flow cytometric cell cycle analysis in 327 fresh specimens of primary breast cancer. "
06/01/2001 - "We monitored cytokeratin (CK)/17-1A positive cells in the bone marrow (BM) and peripheral blood stem cells (PBSC) and studied Her-2/neu serum levels of patients with locally advanced (n = 13; group 1) and metastatic breast cancer (n = 30; group 2) using immunomagnetic separation, immunocytochemistry, and ELISA. "
|2.||Neoplasm Metastasis (Metastasis)
07/01/2009 - "Moreover, the value of CK 17 was significantly higher in T1 and T2 OSCC patients (P < 0.03, respectively), in patients without metastases of neck lymph nodes (P < 0.04), in stage I and stage II patients (P < 0.03 and P < 0.05, respectively) and in well differentiated OSCC patients (P < 0.05). "
04/01/2008 - "The over-expression of CK 17 was significantly associated with metastases of neck lymph nodes (P < 0.05). "
01/01/2006 - "In this study, we retrospectively evaluated the prognostic and predictive impact of c-kit in a high risk subgroup of breast cancer patients (>9 axillary node metastases) who received high-dose (HDCT) or dose-dense (DDCT) conventional chemotherapy and correlated these findings with the expression of the basal-type markers CK5 and CK 17, estrogen (ER) and progesterone (PR) receptor, Her-2/neu and MIB 1. C-kit, CK5, CK17, ER, PR, Her-2/neu and MIBI expression was evaluated immunohistochemically using tissue microarrays containing breast cancer samples from 236 patients who were randomized to the WSG AM01 trial (median follow-up of 60 months). "
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/01/1996 - "CK 10 was expressed only in early squamous cell carcinoma of the bronchus, and CK 17 in varying quantity in hyperplastic, preneoplastic and cancerous lesions of the bronchial mucosa. "
08/01/2012 - "The aim of this study was to confirm the expression profile of cytokeratin (CK)17 in comparison with that of CK13 in oral squamous cell carcinoma (OSCC) and leukoplakia and to clarify an association of CK17 with the OSCC differentiation. "
|5.||Odontogenic Cysts (Keratocyst)
10/01/2005 - "Expression of CK 17 was discernible in 93.3% of the odontogenic keratocysts, but only in 35.0% of dentigerous and radicular cysts under study (P < 0.001). "
10/01/2005 - "Immunohistochemical detection of CK 17 and 19 seems to be a valuable additional parameter distinguishing between odontogenic keratocysts and other odontogenic--especially dentigerous--cysts which clinically are likely the most significant differential diagnoses in this context. "
|8.||Proliferating Cell Nuclear Antigen (PCNA)
|9.||CA-125 Antigen (CA 125 Antigen)
|10.||Complementary DNA (cDNA)
|1.||Drug Therapy (Chemotherapy)